- Home
- LGVN
LGVN
Longeveron Inc.
as 06-26-2025 3:38pm EST
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 23.4M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 138.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $6.40 | Next Earning Date: | 08-13-2025 |
| Revenue: | $2,225,000 | Revenue Growth: | 127.50% |
| Revenue Growth (this year): | -26.34% | Revenue Growth (next year): | 51.48% |
Stock Insider Trading Activity of Longeveron Inc. (LGVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Soffer Rock | LGVN | Director | May 29 '25 | Sell | $1.28 | 21,000 | $26,750.00 | 220,034 | |
| Soffer Rock | LGVN | Director | May 22 '25 | Sell | $1.32 | 2,000 | $2,640.00 | 220,034 | |
| Hare Joshua | LGVN | Chief Scientific Officer | May 16 '25 | Sell | $1.40 | 5,250 | $7,367.33 | 721,796 |
Latest Longeveron Inc. News
LGVN Breaking Stock News: Dive into LGVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 hours ago
Longeveron® Appoints Than Powell as Chief Business Officer
Zacks Small Cap Research
3 days ago
LGVN Announces Pivotal Test Update
GlobeNewswire
3 days ago
Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
GlobeNewswire
18 days ago
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Simply Wall St.
a month ago
Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely
GlobeNewswire
a month ago
Longeveron® to Attend BIO International Convention 2025
GlobeNewswire
a month ago
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
Zacks Small Cap Research
2 months ago
LGVN Entering Crucial Period in Great Shape
Compare LGVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LGVN Longeveron Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.